Patient-Reported Impact of Oncoplastic Breast Conservation Compared to Mastectomy with Reconstruction: A Systematic Review PROMs in O-BCS vs M-R
Abstract
Background: Given the oncologic safety and clinical benefits of oncoplastic breast conservation surgery (O-BCS), we conducted a systematic review to evaluate patient-reported outcomes, including breast satisfaction and physical, psychosocial, and sexual well-being in those undergoing O-BCS compared to mastectomy and reconstruction (M-R). This study aimed to inform clinical decision-making for patients with breast cancer not suitable for standard breast conservation.
Methods: According to PRISMA Guidelines, we identified studies from MEDLINE, Embase, PubMed, and Google Scholar. Studies were included where they compared patient-reported outcomes between O-BCS and M-R using a validated assessment tool such as the BREAST-Q questionnaire. The quality of studies was appraised using the Newcastle-Ottawa Scale (NOS).
Results: Out of the 3434 citations identified by our search, a total of 11 studies were deemed suitable for inclusion, and 9 studies used the validated BREAST-Q assessment tool. There were a total of 1808 O-BCS and 1413 M-R patients. All studies showed improved or equivalent breast satisfaction, psychosocial well-being, and sexual well-being after O-BCS. Physical well-being was reported to be superior in the M-R group. The findings are limited by the moderate to high risk of bias, heterogeneity, variation in outcome measures, differing follow-up durations, and differences in adjustment.
Conclusion: Given the potentially positive impact on patient-reported outcomes, where indicated and feasible, oncoplastic breast-conserving surgery should be offered as a valid surgical alternative to mastectomy and reconstruction as part of a patient-centered individualized treatment approach for breast cancer.
Full text article
References
Noguchi M, Yokoi-Noguchi M, Ohno Y, Morioka E, Nakano Y, Kosaka T, et al. Oncoplastic breast conserving surgery: Volume replacement vs. volume displacement. Eur J Surg Oncol. 2016;42(7):926–34. doi: 10.1016/j.ejso.2016.02.248.
Reid A, Thomas R, Pieri A, Critchley A, Kalra L, Carter J, et al. The impact of advanced oncoplastic surgery on breast-conserving surgery rates: A retrospective cohort study of 3,875 breast cancer procedures at a tertiary referral centre. Breast. 2024;78:103814. doi: 10.1016/j.breast.2024.103814.
Kosasih S, Tayeh S, Mokbel K, Kasem A. Is oncoplastic breast conserving surgery oncologically safe? A meta-analysis of 18,103 patients. Am J Surg. 2020;220(2):385–92. doi: 10.1016/j.amjsurg.2019.12.019.
Mansell J, Weiler-Mithoff E, Stallard S, Doughty JC, Mallon E, Romics L. Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast. 2017;32:179–85. doi: 10.1016/j.breast.2017.02.006.
Mactier M, Mansell J, Arthur L, Doughty J, Romics L. Survival after standard or oncoplastic breast-conserving surgery versus mastectomy for breast cancer. BJS Open. 2025;9(2). doi: 10.1093/bjsopen/zraf002.
Christiansen P, Carstensen SL, Ejlertsen B, Kroman N, Offersen B, Bodilsen A, et al. Breast conserving surgery versus mastectomy: overall and relative survival-a population based study by the Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol. 2018;57(1):19–25. doi: 10.1080/0284186x.2017.1403042.
Christiansen P, Mele M, Bodilsen A, Rocco N, Zachariae R. Breast-Conserving Surgery or Mastectomy?: Impact on Survival. Ann Surg Open. 2022;3(4):e205. doi: 10.1097/as9.0000000000000205.
Jackson KM, Millen JC, Handy N, Orozco JIJ, Stern SL, Fancher CE, et al. Breast Conservation Project: Clinical Outcomes of Extreme Oncoplastic Breast-Conserving Therapy Versus Mastectomy for Large and Multiple Lesions. Ann Surg Oncol. 2024;31(11):7582–93. doi: 10.1245/s10434-024-15799-4.
Ku GC, Desai A, Singhal M, Mallouh M, King C, Rojas AN, et al. Oncoplastic Surgery with Volume Replacement versus Mastectomy with Implant-Based Breast Reconstruction: Early Postoperative Complications in Patients with Breast Cancer. J Reconstr Microsurg. 2024. doi: 10.1055/a-2491-3110.
Di Leone A, Franco A, Terribile DA, Magno S, Fabi A, Sanchez AM, et al. Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience. Cancers (Basel). 2022;14(5). doi: 10.3390/cancers14051275.
Ghilli M, Mariniello MD, Ferrè F, Morganti R, Perre E, Novaro R, et al. Quality of life and satisfaction of patients after oncoplastic or traditional breast-conserving surgery using the BREAST-Q (BCT module): a prospective study. Breast Cancer. 2023;30(5):802–9. doi: 10.1007/s12282-023-01474-1.
Char S, Bloom JA, Erlichman Z, Jonczyk M, Chatterjee A, Guo L. How Does Oncoplastic Surgery Compare with Standard Partial Mastectomy? A Systematic Review of Patient-Reported Outcomes. Plast Reconstr Surg. 2022;150(5):950e–8e. doi: 10.1097/prs.0000000000009616.
Panayi AC, Knoedler S, Knoedler L, Tapking C, Hundeshagen G, Diehm YF, et al. Patient-reported Outcomes Utilizing the BREAST-Q Questionnaire After Breast-Conserving Surgery With and Without Oncoplastic Breast Surgery: A Systematic Review and Meta-analysis. Aesthet Surg J. 2024;44(11):Np778–np89. doi: 10.1093/asj/sjae002.
Pak LM, Matar-Ujvary R, Verdial FC, Haglich KA, Sevilimedu V, Nelson JA, et al. Long-Term Patient-Reported Outcomes Comparing Oncoplastic Breast Surgery and Conventional Breast-Conserving Surgery: A Propensity Score-Matched Analysis. Ann Surg Oncol. 2023;30(12):7091–8. doi: 10.1245/s10434-023-13962-x.
Araujo Pereira Lisboa FC, Paulinelli RR, Campos Veras LP, Jube Ribeiro LF, Padua Oliveira LF, Sousa Rahal RM, et al. Aesthetic results were more satisfactory after oncoplastic surgery than after total breast reconstruction according to patients and surgeons. Breast. 2023;71:47–53. doi: 10.1007/s10549-021-06126-6.
Mason EJ, Di Leone A, Franco A, D'Archi S, Rianna C, Sanchez AM, et al. Oncoplastic Breast Surgery versus Conservative Mastectomy in the Management of Large Ductal Carcinoma In Situ (DCIS): Surgical, Oncological, and Patient-Reported Outcomes. Cancers (Basel). 2022;14(22). doi: 10.3390/cancers14225624.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71. doi: 10.1136/bmj.n71.
Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009;124(2):345–53. doi: 10.1097/PRS.0b013e3181aee807.
Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World Journal of Meta-Analysis. 2017;5(4):80–4. doi: 10.13105/wjma.v5.i4.80.
Wang Y, He Y, Wu S, Xie S. Disparities in quality of life among patients with breast cancer based on surgical methods: a cross-sectional prospective study. Sci Rep. 2024;14(1):11364. doi: 10.1038/s41598-024-62105-z.
Sagiroglu J, Ozemir IA, Eren T, Akkin F, Gapbarov A, Okur O, et al. Comparison of Oncoplastic Breast Surgery, Non-oncoplastic Breast Conserving Surgery and Mastectomy in Early Breast Cancer: A Single Center Retrospective Study. Arch Iran Med. 2021;24(5):390–6. doi: 10.34172/aim.2021.56.
Xu Y, Cao J, Gong K, Li S, Liu Y, Xiong F, et al. Oncoplastic breast-conserving surgery improves cosmetic outcomes without increasing recurrence risk compared to modified radical mastectomy in early breast cancer patients: development and validation of a recurrence risk prediction model. Am J Cancer Res. 2023;13(9):4259–68.
Oei SL, Thronicke A, Grieb G, Schad F, Groß J. Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data. Breast Cancer. 2023;30(6):1008–17. doi: 10.1007/s12282-023-01494-x.
Bazzarelli A, Baker L, Petrcich W, Zhang J, Arnaout A. Patient Satisfaction Following Level II Oncoplastic Breast Surgery: A Comparison with Mastectomy Utililizing the Breast-Q Questionnaire will be published in Surgical Oncology. Surg Oncol. 2020;35:556–9. doi: 10.1016/j.suronc.2020.11.001.
Ritter M, Ling BM, Oberhauser I, Montagna G, Zehnpfennig L, Lévy J, et al. The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery. Breast Cancer Res Treat. 2021;187(2):437–46. doi: 10.1007/s10549-021-06126-6.
Rautalin M, Jahkola T, Roine RP. Surgery and health-related quality of life - A prospective follow up study on breast cancer patients in Finland. Eur J Surg Oncol. 2021;47(7):1581–7. doi: 10.1016/j.ejso.2021.02.006.
Kelsall JE, McCulley SJ, Brock L, Akerlund MTE, Macmillan RD. Comparing oncoplastic breast conserving surgery with mastectomy and immediate breast reconstruction: Case-matched patient reported outcomes. J Plast Reconstr Aesthet Surg. 2017;70(10):1377–85. doi: 10.1016/j.bjps.2017.05.009.
Bolliger M, Lanmüller P, Schuetz M, Heilig B, Windischbauer A, Jakesz R, et al. The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center study. Int J Surg. 2022;104:106694. doi: 10.1016/j.ijsu.2022.106694.
Gulis K, Ellbrant J, Bendahl PO, Svensjö T, Rydén L. Health-related quality of life by type of breast surgery in women with primary breast cancer: prospective longitudinal cohort study. BJS Open. 2024;8(3). doi: 10.1093/bjsopen/zrae042.
Davies C, Johnson L, Conefrey C, Mills N, Fairbrother P, Holcombe C, et al. Clinical and patient-reported outcomes in women offered oncoplastic breast-conserving surgery as an alternative to mastectomy: ANTHEM multicentre prospective cohort study. Br J Surg. 2024;112(1). doi: 10.1093/bjs/znae306.
Foley A, Choppa A, Bhimani F, Gundala T, Shamamian M, LaFontaine S, et al. Oncoplastic breast-conserving surgery (OBCS) vs. mastectomy with reconstruction: a comparison of outcomes in an underserved population. Gland Surg. 2024;13(3):358–73. doi: 10.21037/gs-23-403.
Koppiker CB, Kelkar DA, Kulkarni M, Kadu S, Pai M, Dhar U, et al. Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy. Front Oncol. 2023;13:1176609. doi: 10.3389/fonc.2023.1176609.
Chand ND, Browne V, Paramanathan N, Peiris LJ, Laws SA, Rainsbury RM. Patient-Reported Outcomes Are Better after Oncoplastic Breast Conservation than after Mastectomy and Autologous Reconstruction. Plast Reconstr Surg Glob Open. 2017;5(7):e1419. doi: 10.1097/gox.0000000000001419.
Flanagan MR, Zabor EC, Romanoff A, Fuzesi S, Stempel M, Mehrara BJ, et al. A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction. Ann Surg Oncol. 2019;26(10):3133–40. doi: 10.1245/s10434-019-07548-9.
Lim DW, Retrouvey H, Kerrebijn I, Butler K, O'Neill AC, Cil TD, et al. Longitudinal Study of Psychosocial Outcomes Following Surgery in Women with Unilateral Nonhereditary Breast Cancer. Ann Surg Oncol. 2021;28(11):5985–98. doi: 10.1245/s10434-021-09928-6.
Hanson SE, Lei X, Roubaud MS, DeSnyder SM, Caudle AS, Shaitelman SF, et al. Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction. JAMA Surg. 2022;157(6):e220631. doi: 10.1001/jamasurg.2022.0631.
Pinto CA, Peleteiro B, Pinto CS, Osório F, Costa S, Magalhães A, et al. Breast cancer patient-reported outcomes on level 1 and level 2 oncoplastic procedures using BREAST-Q(®). J Cancer Res Clin Oncol. 2023;149(7):3229–41. doi: 10.1007/s00432-022-04228-2.
Ku GC, Wareham C, King C, Koul A, Desai A, Persing SM, et al. Is Oncoplastic Surgery Safe in High-Risk Breast Cancer Phenotypes? J Surg Oncol. 2025;131(2):133–42. doi: 10.1002/jso.27899.
Millen JC, Sibia U, Jackson K, Stern SL, Orozco JIJ, Fancher CE, et al. Comparing Costs: Does Extreme Oncoplastic Breast-Conserving Surgery Confer a Cost Benefit When Compared with Mastectomy and Reconstruction? Ann Surg Oncol. 2024;31(11):7463–70. doi: 10.1245/s10434-024-15711-0.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386(6):556–67. doi: 10.1056/NEJMoa2112651.
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.